Barinthus Biotherapeutics (BRNS) Other Non-Current Liabilities (2021 - 2026)

Barinthus Biotherapeutics (BRNS) has 6 years of Other Non-Current Liabilities data on file, last reported at $1.5 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 4.86% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 4.86% YoY) and the FY2025 annual result came in at $1.5 million, up 8.53% from the prior year.
• Other Non-Current Liabilities retreated to $1.5 million in Q1 2026, from $1.5 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $2.5 million in Q2 2025 to a low of $434000.0 in Q1 2022.
• A 5-year average of $1.5 million and a median of $1.4 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities plunged 59.3% — and 2023, when it surged 294.01%.
• Tracing BRNS's Other Non-Current Liabilities over 5 years: stood at $965000.0 in 2022, then soared by 88.91% to $1.8 million in 2023, then decreased by 25.4% to $1.4 million in 2024, then rose by 8.53% to $1.5 million in 2025, then slipped by 0.54% to $1.5 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $1.5 million (Q1 2026), $1.5 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.